The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> September 6, 2012

PDL BioPharma, Inc. (PDLI)

McLaughlin, John P.
John P. McLaughlin was elected a Director of PDL BioPharma, Inc., in October 2008. He has been the company’s President and Chief Executive Officer since December 2008, after the company spun off Facet Biotech Corporation. From November 2008 until the spinoff, he served as a Senior Adviser to the company. He was the CEO and a Director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, he held several senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a Partner at a Washington, D.C., law firm specializing in food and drug law. Before that, he served as Counsel to various subcommittees in the U.S. House of Representatives, where he drafted numerous measures that became FDA laws. Mr. McLaughlin cofounded and served as Chairman of the board of directors of Eyetech Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, subsequently bought by OSI Pharmaceuticals, Inc. He cofounded and served as a Director of Peak Surgical, Inc., a privately held medical device company, subsequently purchased by Medtronic, Inc. Mr. McLaughlin serves as a Director of Seattle Genetics, Inc., a publicly traded biopharmaceutical company. He received a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America. Profile
TWST: Please begin with a brief overview of PDL BioPharma?

Mr. McLaughlin: Sure. PDL is a biotech company. We're publicly traded, and we're a little different from most biotech

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy